Endocrinology

Top Story

Glucocorticoid replacement doses tied to mortality risk in nonfunctioning pituitary adenoma

June 27, 2017

Patients with nonfunctioning pituitary adenoma who receive daily hydrocortisone replacement doses greater than 20 mg are at increased risk for death from any cause vs. similar patients receiving lower doses and those without secondary adrenal insufficiency, according to findings published in the European Journal of Endocrinology.

“The previously demonstrated excess mortality in patients with adrenal insufficiency has been mainly attributable to cardiovascular, respiratory and infectious diseases as well as cancer,” Daniel S. Olsson, MSc, MD, PhD, of the Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden, and colleagues wrote. “It is likely that the degree of adrenal insufficiency is of importance for outcome and that patients who are completely insufficient may be more vulnerable to intercurrent illness, whereas patients with partial [adrenocorticotropic hormone] deficiency may be overtreated under normal unstressed conditions using conventional replacement doses. Hence, inadequate treatment of hypocortisolism remains a significant cause of death during stressful events and intercurrent illness in patients with hypopituitarism.”

‘Lives of our patients are at stake’ as concerns about Senate health care bill mount

June 27, 2017
The cost savings that would be realized under the Senate’s proposed health care bill would have a dramatic negative effect on the quality of health care offered in…
In the Journals

Mortality risk likely to be higher among uninsured patients

June 27, 2017
With the Congressional Budget Office report indicating that 22 million Americans will lose insurance coverage by 2026 under
In the Journals PlusPerspective

Grading system may predict recurrence, progression of pituitary neuroendocrine tumors

June 27, 2017
The risk for recurrence or progression of pituitary neuroendocrine tumors in adults is significantly associated with age and tumor type, according to findings published…
FDA News

FDA releases plan to expedite, promote generic drug development

June 27, 2017
As part of its effort to increase competition in the prescription drug market, the FDA released a list of drugs that are off-patent and off-exclusivity without approved…
More News Headlines »
CME

Practical Lipidology®: Volume 3, Number 2

This activity is supported by an educational grant from Amgen

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing…
More »
Video
Meeting News

VIDEO: Beta-cell replacement will be future of diabetes care

June 9, 2017
More »
Featured
The Endocrine Society Annual Meeting

The Endocrine Society Annual Meeting

CNE CME CPE

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »
Current Issues
View the Current Issue
Advertisement
Advertisement